- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06364371
Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer
A Study of the Clinical Value of Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer (T3-4NxM0)
The goal of this observational study is to establish a dynamic multi-omics integration model for predicting pathological complete response (pCR) after neoadjuvant treatment in locally advanced (T3-4NxM0) rectal cancer, providing support for subsequent patient selection for the watch-and-wait strategy. The main question it aims to answer is:
What is the predictive value of this model to assess individual achievement of pathological complete response (pCR) after neoadjuvant treatment? Eligible patients will be prospectively enrolled, and the clinical features of their pre-neoadjuvant treatment, during-treatment, and post-treatment preoperative will be collected and annotated.
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a single-center, prospective, observational phase II clinical study aimed at validating a dynamic multi-omics (imaging, pathology, molecular biomarkers) integration model for predicting pathological complete response (pCR) after neoadjuvant treatment in locally advanced (T3-4NxM0) rectal cancer. Specifically, the study aims to validate the predictive accuracy of the dynamic multi-omics prediction model and determine whether it outperforms other conventional prediction models based on single-modality imaging, pathology, and molecular biomarkers.
Eligible patients will be prospectively enrolled, and images of their pre-neoadjuvant treatment, during-treatment, and post-treatment preoperative magnetic resonance imaging (MRI) scans, histopathology slides stained with hematoxylin and eosin (H&E), carcinoembryonic antigen (CEA), and circulating tumor DNA (ctDNA) will be collected and annotated. MRI, H&E images, CEA, ctDNA, and their change features will be applied to the prediction model to assess individual achievement of pathological complete response (pCR) after neoadjuvant treatment. The predictive results will be further compared with the pathological tumor response obtained from resected specimens.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Jun Huang
- Phone Number: +86-13926451242
- Email: huangj97@mail.sysu.edu.cn
Study Contact Backup
- Name: Meijin Huang
- Phone Number: +86-13924073322
- Email: meijinhuang3@163.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Recruiting
- The Sixth Affiliated Hospital, Sun Yatsen University
-
Contact:
- Jun Huang
- Phone Number: 13926451242
- Email: huangj97@mail.sysu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Histologically confirmed rectal adenocarcinoma;
- Clinical stage T3-4NxM0, with or without positive Mesorectum Fascia(MRF), and with or without positive Extra-Mural Venous Invasion(EMVI);
- Preoperative staging method: All patients undergo preoperative staging with enhanced CT. Criteria for mesorectal lymph node metastasis: Short axis ≥ 10mm lymph nodes or lymph node morphology and CT characteristics consistent with typical lymph node metastasis. Preoperative chest, abdominal CT, and pelvic MRI exclude distant metastases;
- Absence of signs of intestinal obstruction; or relief of obstruction after proximal colon diversion surgery;
- No history of previous colorectal surgery;
- No history of previous chemotherapy or radiotherapy;
- No history of previous biological therapy (such as monoclonal antibodies), immunotherapy [such as anti-programmed cell death protein 1(PD-1) antibodies, anti-PD-L1 antibodies, anti-PD-L2 antibodies, or anti-Cytotoxic T Lymphocyte-Associated Antigen-4(CTLA-4)], or other investigational drug therapy;
- No history of previous hormonal therapy: no restrictions;
- Signed informed consent form.
Exclusion Criteria:
- Patients requiring antiarrhythmic therapy (excluding β-blockers or digoxin), symptomatic coronary artery disease, recent myocardial infarction within the past 6 months, or congestive heart failure exceeding New York Heart Association(NYHA) class II;
- Poorly controlled severe hypertension;
- History of HIV infection or active chronic hepatitis B or C (high viral DNA load);
- Active pulmonary tuberculosis (TB) or receiving anti-TB treatment, or having received anti-TB treatment within the past year;
- Other active clinically severe infections ;
- Evidence of distant metastases outside the pelvis preoperatively;
- Cachexia, organ decompensation;
- History of pelvic or abdominal radiotherapy;
- Multifocal colorectal cancer;
- Patients requiring management for epileptic seizures (e.g., with steroids or antiepileptic therapy);
- History of other malignant tumors within the past 5 years, excluding cured carcinoma in situ of the cervix or basal cell carcinoma of the skin;
- Substance abuse or medical, psychological, or social conditions that may interfere with patient participation in the study or assessment of study results;
- Presence of any active autoimmune disease or history of autoimmune disease (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, nephritis, hyperthyroidism, hypothyroidism; patients with vitiligo or childhood asthma that has completely resolved and does not require any intervention in adulthood may be included; patients with asthma requiring bronchodilators for medical intervention cannot be included);
- Vaccination with any anti-infective vaccine (e.g., influenza vaccine, varicella vaccine, etc.) within 4 weeks before enrollment;
- Complications requiring long-term use of immunosuppressive drugs or systemic or local administration of corticosteroids with immunosuppressive effects (dose > 10mg/day of prednisone or equivalent corticosteroids);
- Known or suspected allergy to the investigational drug or any medication administered related to this trial;
- Any unstable condition or situation that may jeopardize patient safety and compliance;
- Pregnancy or lactation in women of childbearing potential who have not taken adequate contraceptive measures;
- Refusal to sign the informed consent form.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Observational cohort
Patients with locally advanced (T3-4NxM0) rectal adenocarcinoma
|
Eligible patients will be prospectively enrolled, and images of their pre-neoadjuvant treatment, during-treatment, and post-treatment preoperative magnetic resonance imaging (MRI) scans, histopathology slides stained with hematoxylin and eosin (H&E), carcinoembryonic antigen (CEA), and circulating tumor DNA (ctDNA) will be collected and annotated.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under curve(AUC)
Time Frame: through study completion, an average of 6 months
|
Area under curve of prediction model
|
through study completion, an average of 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity
Time Frame: through study completion, an average of 6 months
|
Sensitivity of prediction model
|
through study completion, an average of 6 months
|
Specificity
Time Frame: through study completion, an average of 6 months
|
Specificity of prediction model
|
through study completion, an average of 6 months
|
Negative predictive value(NPV)
Time Frame: through study completion, an average of 6 months
|
negative predictive value of prediction model
|
through study completion, an average of 6 months
|
Positive predictive value(PPV)
Time Frame: through study completion, an average of 6 months
|
positive predictive value of prediction model
|
through study completion, an average of 6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jun Huang, Sun Yat-sen University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- E2023210
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Predictive Cancer Model
-
Tianjin Medical University Cancer Institute and...Sun Yat-sen University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaboratorsCompletedSolid Tumor | Predictive Cancer ModelChina
-
Military University Hospital, PragueRecruitingPredictive Cancer ModelCzechia
-
Known Medicine, Inc.M.D. Anderson Cancer Center; Mayo Clinic; Duke Cancer InstituteRecruitingCancer | Effects of Chemotherapy | Predictive Cancer ModelUnited States
-
Air Force Military Medical University, ChinaCompletedColonoscopy | Bowel Preparation | Predictive ModelChina
-
Ningbo No. 1 HospitalCompletedColonoscopy | Predictive Model | External ValidationChina
-
Air Force Military Medical University, ChinaShenzhen Hospital of Southern Medical University; Huaihe Hospital of Henan... and other collaboratorsCompletedColonoscopy | Bowel Preparation | Predictive ModelChina
-
University Hospital, GenevaQIAGEN Gaithersburg, Inc; Hologic, Inc.; Pregnolia ACCompletedLabor Onset | Labor, Induced | Labor, Obstetric | Predictive ModelSwitzerland
-
Radboud University Medical CenterCompletedPredictive Cancer ModelNetherlands
-
Chinese PLA General HospitalPeking University First Hospital; Xiangya Hospital of Central South University and other collaboratorsCompleted
-
Fudan UniversityRecruitingMetastasis | Predictive Cancer ModelChina
Clinical Trials on Medical examination
-
National Cancer Institute (NCI)Active, not recruitingProstate CarcinomaUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedLymphedemaUnited States
-
Tokat Gaziosmanpasa UniversityCompletedReferral and Consultation
-
Ohio State University Comprehensive Cancer CenterCompletedTongue Cancer | Lip and Oral Cavity Squamous Cell Carcinoma | Oral Cavity Verrucous Carcinoma | Stage 0 Lip and Oral Cavity CancerUnited States
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); University of Arkansas; Tata Memorial Hospital; Udaan TrustNot yet recruitingHIV InfectionUnited States, India
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedEndometriosis | Cervicovaginitis | Repeated Implantation FailureItaly
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedType 1 Diabetes | Type 2 DiabetesItaly
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedNon Small Cell Lung Cancer | Metastatic MelanomaItaly
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Catholic University of the Sacred Heart; Institute of Biomembranes, Bioenergetics... and other collaboratorsCompletedHepatic Encephalopathy | Irritable Bowel Syndrome | Clostridium Difficile Infection | Chronic Inflammatory Bowel Disease | Multi Drug Resistant OrganismsItaly
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedAutosomal Dominant Polycystic Kidney Disease (ADPKD) | IgA Nephropathy (IgAN) | Diabetic Kidney Disease (DKD) | Advanced-Chronic Kidney Disease (CKD)Italy